Genentech Addresses Speculative Buying; No Distortions From March 1 Hikes

Genentech has effectively eliminated speculative buying by drug wholesalers in advance of price increases, Exec VP-Commercial Operations Myrtle Potter declared in an April 9 analyst call

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet